Lucid Diagnostics Inc. Stock Price, News & Analysis

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference is scheduled for February 11-12, 2024, at the Cliff Lodge in Snowbird, UT.

Shaun O'Neil, who serves as Lucid's President and Chief Operating Officer, will be available for one-on-one meetings throughout the conference. Interested investors are advised to contact their BTIG representative to schedule meetings.

Lucid Diagnostics (LUCD) reported record-breaking quarterly performance for its EsoGuard® Esophageal DNA Tests in Q4 2024, with 4,042 tests completed. This represents a 45% increase from Q3 2024 and an 84% year-over-year growth from Q4 2023.

The company is focusing on three key commercial revenue drivers: traditional claims submissions, direct contracting with employers and self-insured entities, and a new cash pay program targeting concierge medicine practices. Lucid aims to secure Medicare coverage and expects these initiatives to boost revenue growth and expand EsoGuard testing accessibility.

Full financial results for Q4 and full-year 2024 are expected to be released in mid-March 2025. The current figures are preliminary and subject to quarter-end closing and audit procedures.

Lucid Diagnostics (Nasdaq: LUCD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until June 16, 2025 to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The notification does not immediately affect LUCD's listing status, and shares will continue trading on the Nasdaq Capital Market. The company plans to take appropriate actions to regain compliance before the deadline.

Lucid Diagnostics (LUCD) has formed a strategic partnership with VITALExam to enhance access to its EsoGuard® Esophageal DNA Test for firefighters at risk of esophageal precancer. The partnership launched with a #CheckYourFoodTube Precancer Testing Event at Tuscaloosa Fire Rescue, as part of Lucid's expanded direct contracting initiative aimed at driving near-term EsoGuard revenue.

The collaboration is particularly significant as firefighters face a 62% increased risk of developing esophageal cancer and a 39% increased risk of dying from it. VITALExam, founded by Dr. Marci Vitale, specializes in providing comprehensive medical care for first responders, including cancer screenings and comprehensive physicals.

Lucid Diagnostics (NASDAQ: LUCD) announced the acceptance of its CLUE study manuscript for publication in Medicina, marking the fourth peer-reviewed publication supporting EsoGuard's clinical utility. The study demonstrated exceptional results, including 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing.

The prospective, multicenter study enrolled 502 patients across eight clinical centers, showing strong provider decision impact: 100% of EsoGuard-positive patients were referred for confirmatory EGD, while over 99% of EsoGuard-negative patients were not referred. The compliance rate was more than double the typical screening EGD referral rate in published literature.

Lucid Diagnostics has completed a convertible debt refinancing transaction that strengthens its financial position. The company issued five-year convertible notes worth $21.95 million to long-term equity shareholders. After retiring $3.61 million of existing convertible debt, the transaction yielded $18.34 million in net cash proceeds. This increases Lucid's pro forma cash to approximately $33 million as of Q3 end, extending its cash runway past key reimbursement milestones. The new convertible debt is structured to keep shares out of the market.

Lucid Diagnostics (LUCD) has submitted a clinical evidence package to MolDX seeking Medicare coverage for its EsoGuard® Esophageal DNA Test. The submission includes six new peer-reviewed publications, comprising three clinical validation studies, two clinical utility studies, and one analytical validation study. The package supports a Request for Reconsideration of Local Coverage Determination (LCD) L39256, aiming to secure Medicare coverage for EsoGuard testing. The company believes the data demonstrates strong clinical validity, utility, and analytical accuracy, particularly highlighting EsoGuard's precancer detection performance across all studies.

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention medical diagnostics company and PAVmed subsidiary, announced its upcoming presentation at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York. The presentation is scheduled for Thursday, November 21, 2024, at 1:30 p.m. ET.

Investors can access both live and replay webcasts through the company's investor relations website at ir.luciddx.com. The webcast recording will remain available for a minimum of 30 days following the event.

PAVmed reported key developments in Q3 2024, including record quarterly EsoGuard® revenue of $1.2M, representing a 20% sequential increase. Lucid performed 2,787 commercial EsoGuard tests in Q3, with October seeing a record 1,400+ tests. The company completed Lucid's deconsolidation and is finalizing debt restructuring to maintain Nasdaq listing compliance. PAVmed reported Q3 operating expenses of $12.6M and GAAP net income of $64.3M. Cash position stood at $0.8M as of September 30, 2024, compared to $19.6M at end of 2023.